



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 166 798 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.01.2002 Bulletin 2002/01

(51) Int Cl.7: A61K 45/06

(21) Application number: 00250194.8

(22) Date of filing: 23.06.2000

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: Schering Aktiengesellschaft
13353 Berlin (DE)

(72) Inventors:
• Siemeister, Gerhard
13503 Berlin (DE)
• Haberey, Martin, Dr.
12169 Berlin (DE)
• Thierauch, Karl-Heinz, Dr.
14169 Berlin (DE)

(54) Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/NGF re-

ceptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurstonen et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab. Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0006] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine

kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

[0007] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

[0008] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

[0009] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.


[0010] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0011] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic


agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- 5 (a) compounds which inhibit receptor tyrosine kinase activity,
 - (b) compounds which inhibit ligand binding to receptors,
 - (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
- 15 [0012] A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. 20 Assoc. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Assoc. Cancer Res., San Franzisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is 25 prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as Pseudomonas exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer 30 Res. 57, 4593-4599. Ligand-binding receptor domaines are described by Kendall & Thomas (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579.
- Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- 35 or receptor binding oligo nucleotides habe been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.
- [0013] Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, An-giozyme™, see RPI Homepage).
- 40 [0014] Examples for delivery-/Targeting-Systems have been described as ligand/ antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).
- [0015] Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I




in which

- 20 r has the meaning of 0 to 2,
 n has the meaning of 0 to 2;
 R₃ und R₄ a) each independently from each other have the meaning of lower alkyl,
 b) together form a bridge of general partial formula II,
- 25



- m wherein the binding is via the two terminal C- atoms, and
 has the meaning of 0 to 4; or
 c) together form a bridge of partial formula III

40



50

wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T₁ and T₄:

G has the meaning of C₁ - C₆ - alkyl, C₂ - C₆ - alkenylene or C₂ - C₆ - alkynylene; or C₂ - C₆ - alkenylene or C₃ - C₆ - alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂, oxa (-O-), thia (-S-) or imino (-NH-),

55 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,

EP 1 166 798 A1

R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
 X has the meaning of imino, oxa or thia;
 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or
 substituted cycloalkyl; and
 5 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N, N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkyl-sulfonyl, or alkylphenylsulfonyl, whereas, if more
 10 than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygen atom, or a salt thereof.


[0016] A preferred salt is the salt of an organic acid, especially a succinate.

15 [0017] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.
 [0018] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranyl acid derivatives of general formula IV

20

25


30



35 in which

A has the meaning of group =NR²,
 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,
 Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-
 40 Alkyl or is the group



45




50

or A, Z and R¹ together form the group

55




m, n and o	has the meaning of 0 - 3,
q	has the meaning of 1 - 6,
R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and/ or R _d or R _c together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
X	has the meaning of group =NR ⁹ or =N-,
Y	has the meaning of group -(CH ₂) _p ,
P	has the meaning of integer 1-4,
R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy,
R ⁴ , R ⁵ , R ⁶ and R ⁷	independently from each other have the meaning of hydrogen, halogen or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or C ₁₋₆ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R ⁵ and R ⁶ together form the group



R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

[0019] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0020] More preferentially compounds of general formula V




15

in which

R¹ has the meaning of group


20

25




30

35

in which R⁵ is chloro, bromo or the group -OCH₃,


40

45

in which R⁷ is -CH₃ or chloro,

50

55




in which R⁸ is -CH₃, fluoro,
chloro or -CF₃

in which R⁴ is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or

in which R⁶ is
-CH₃ or chloro

R^2 has the meaning of pyridyl or the group



and

R³ has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

[0021] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneic diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

35 The above mentioned compounds are also claimed matter within the inventive combinations.

[0022] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

[0023] Claimed matter of the instant invention are therefore pharmaceutical compositions

40

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.

45

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to

the endothelium via one or several of the Angiopoietin/Tie receptor systems,

5 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

10 g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

15 h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

[0024] For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

[0025] The inventive compositions comprise as compound I or as compound II at least one of

20 a) compounds which inhibit receptor tyrosine kinase activity,

b) compounds which inhibit ligand binding to receptors,

c) compounds which inhibit activation of intracellular signal pathways of the receptors,

d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

25 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

[0026] Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.

[0027] Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

[0028] The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen

40 succinates Tie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

[0029] The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

55 [0030] Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organ-

ically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

[0031] For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

[0032] The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

[0033] These formulations and application forms are also part of the instant invention.

[0034] Combined functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

[0035] The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

[0036] VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

[0037] Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

[0038] Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiobromia, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thromboc microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

[0039] The following example demonstrates the feasibility of the disclosed invention, without restricting the invention to the disclosed example.

Example 1

[0040] Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

[0041] Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor [4-Chlorophenyl][4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

	mode of treatment	
5 treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
10 Group 1: A375v/pCEP	-	-
15 Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
15 Group 4: A375v/sTie2	+	+

5 [0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Description of the figures

30 20 [0043] Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

35 mock, con. = treatment group 1
mock+VEGF-A = treatment group 2
sTIE2-c113 = treatment group 3
sTIE2-c113+VEGF-A = treatment group 4

40

45

50

55

Sequenzprotokoll

<110> Schering Aktiengesellschaft

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use

<130> 51849AEPM1XX00-P

<140>

<141>

<160> 59

<210> 1

<211> 1835

<212> DNA

<213> Human

<400> 1

ttttacagtt ttcctttct tcagagttaa ttttgaattt tcattttgg ataaccaagc 60
 agctcttaa gaagaatgca cagaagagtc attctggcac tttggatag tacataagat 120
 tttctttttt ttttttaat ttttttaat agtcacattc agctcgcttg ctcaaaccag 180
 actcccacat tgggtgagca agatgagccc ataggattcc agagttata cgtaaccgt 240
 tatacaaaca gccaaaaaac cataatggtg ccacaggat ggagcagggaa agggcatctc 300
 taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
 agcacactgt gttgaaacga ggtatgtgc cccaaatggc acttggcagc atgcagtta 420
 aagcaaaaaga gacatccctt aataactgta taaaatcccg gcagttccat taaagggggt 480
 aagaaaaacc aacaacaacaa aaagcgaggg actgtctgtt gtcaactgtca aaaaggcact 540
 tgaggttaat gggaccagga ttggaggact cttagctgtat acagattca gtacgatttc 600
 attaaaaggc ttggatgtta agagaggaca ctcagcggtt cctgaagggaa gacgctgaga 660
 tgaccgctg agaagcgaa cagatgaaca caaaggaaatc aaatctttac aaccaaattt 720
 catttaagcg acaacaaaaa aaggcaaaacc caaaacgcgca acctaaccaa agcaaaatct 780
 aagcaaaatc agacaacgaa gcagcgatgc atagcttcc ttgagagaa cgcatacctt 840
 gagacgctac gtgccaacctt aagtgtctaa cgacagcttc acagtaggat tattgtata 900
 aaaatgactc aagcgtatc aaaatgttca tctgttccca gaatccgagg gagaactgag 960
 gtgatcgtaa gaggcatagcg acatcacgtg cggtttctta atgtccctgg tggcgatatac 1020
 gccgagtctt cggaaaggaca tctggacacc actttcagcc accttccttc agggcgaca 1080
 tccgccaaag tcatcctta ttccgagtaa taactttat tcctttctaa catttacacg 1140
 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgccc gttccgtttc 1200
 ctccacgaaac gggtacgcmc ttccatgaga aaggatattt ggcaattttt tattccacag 1260
 tcaggtgggt ctgcgtatgc tcatttaatg ttaaacgcac tcaggggctt ctcctccctgt 1320
 ttctgccagg ggctttctt gtcttcctt tggcgagctc gtggcgagat cttctcttgt 1380
 gggggctggc tgctggctcc gagggggcat cccgagtcgg tctggctgtc tccctctgca 1440
 ggctgggcagc ctggccacca ctctccgac tcgacccttc caacaaggcat cgcaggcaca 1500
 tgtcctcggg ggtacagacc gtggcccac attcgttacc actctgttcc acgtcatcca 1560
 ggtacacgag ctgcgtgttag gccgtgtgt ctggggctcg aggcttttgc tgctgtgt 1620
 ctggacggg cgggtatgtc tgctgcagag acaaaggcatc tcccccttcc ttccgggctg 1680
 attttggttc attcatatct acgcacagat ccaaactggc atcattactt ccgttccttc 1740
 cagctctttg gagaatcaat gtataaatgt ctaacctgac cggtggaccc gccatccaag 1800
 gagacgaacc acgcccgggg gtgcggaaagc ggcct

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

gttctagatt gttttattca gtaatttagct cttaaagaccc ctggggcctg tgctacccag 60
 acactaacaa cagtctctat ccagggtgtc gttctgggtg acgtgatctc cccatcatga 120

tcaacttact tcctgtggcc cattagggaa gtggtgaccc cgggagctat ttgcctgtt 180
 agtgcacaca cctggaaaca tactgtctc atttttcat ccacatcagt gagaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacattca 300
 5 ttattacag gactaaaagt tcattattgt ttgtaaagga tgaattata acctctgcag 360
 agttatagttt catacacagt tgatccat ttataaaggc agaaaagtcct tggatgtt 420
 aaatgtcaag ctggactga aaactcccg tttccagtc actggagtgt gtgcgtatga 480
 aaaaaaatctt tagcaatta gatgggagag aaggaaataa gtacttgaaa tgtaggccct 540
 caccccccata tgacatcctc catgagcctc ctgtatgt g

 10 <210> 3
 <211> 516
 <212> DNA
 <213> Human

 <400> 3

 15 tagagatgtt gggtgatgac cccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtcata tacatcacag aggacatgtt catgtcgcgg aacctgaatg 120
 gacactctgg gttgatgtt aaagaattt ggttccatc ctcgagctt tcagaaacag 180
 ttgttaaggtt tcgtggccat agtactgtt ctcttccaca gactatgtt cgaaaaccaa 240
 20 agacccatccatc tgcacac agtgcgtt tgcgtatgtt cagatccatc cagaaagact 300
 tcctgcgtatc tgcaggctt tgcgttgcata ctgctcgtt ttacacccatc ggatgtggcc 360
 atgaactggtt tgaggaaggc ctctattgttca acagttgtt ggcggcggc tgcataaca 420
 tccaagatgtt tttccatgtt aaaagaacca gcaaataactt ttctctggat ctcactcatg 480
 atgaagttcc agagttgtt gtgtaaagtc cgtctg

 <210> 4
 25 <211> 1099
 <212> DNA
 <213> Human

 <400> 4

 30 cccacaacac agggggccctg aaacacgcca gccttcctc tgggtcagc ttggcccaat 60
 cctgctcact ggatcacatc ccattgttgggatggatcgg ggccttggc 120
 ccacggggatc gtagaagaag acctggatccg tggatggatc tggatggatc 180
 ggggtgcgtt ttggccatc cgtccatc tccccccgtt gaggcagcgtt cacagcagg 240
 gacccaaactt cagcaggatc agcaccaggc agatgttgc aaccaccaat atgaagatgt 300
 tgaagatgtt ctcttcgtt gggcggatc acaaaccatc caccatgtt caccatgtt 360
 35 ctgcgttgcata cacaacacatc ggctccatgtt tccagccgtt caggccatc tggccatata 420
 ggaagcctgtt ctcttagatc ctcttcgttgc gacactgttgc gacatgttgc cccatgtt 480
 ctccgcggat ggcggcgtt ccatttcgtt ccaccgtatc ttggccatc tgacgttgc 540
 cggccgcgtt cggccgttcc acctgttgggt cttggccgtt cagtgccgc agctccctt 600
 ctcttcgttgc cagccgttgc tctcgccatc acaggatataat gacatggccatc aggttagatca 660
 ggggtgggtgtt gctgacgttgc aggaactgttgc gacccatgttgc gggatgttgc gagatgggg 720
 40 aggccgttgc atagcagatc ttgggtcagc ctgggtggcc cgtgttacatc tcgaaatctg 780
 actgtcgttgc accccacact gactgtccggc cggggccatc gatgttgcgtt cggaaatgt 840
 agagcaccgtt cagccatgttgc ttaccatgttgc cggatgttgc tccctggatc tggatgttgc 900
 acttctccatc gaagccatgttgc tcaccatgttgc tccctggccatc tccgttgcata agggatgttgc 960
 gcacgttgcgtt gttgttgcgttgc ggcacatgttgc tccgttgcgttgc agcaacaatgttgc ctgcagggtt 1020
 qtctgttgcgtt cccgttgcgttgc cggccgttgcgttgc cggggccatc cggatgttgcgtt 1080
 45 gggccggatgtt acggccatgttgc

 <210> 5
 <211> 1015
 <212> DNA
 <213> Human

 50 <400> 5

 gaggataggg agcctgggtt caggatgttgc ggagacacatc cgagactctg tctccaaaaa 60
 aaaaaatgttgc ttttggatgttgc aatgttgcgtt aaccaatgttgc ttttggatgttgc 120
 agtggggatc ataatgttgc acacccatgttgc gttgttgcgttgc ttttggatgttgc 180
 55 ttggggatc gccatgttgc tccctggccatc ggttgcgttgc ttttggatgttgc 240
 ccagacccatc gaggatgttgc tccctggccatc ggttgcgttgc ttttggatgttgc 300
 gccttcgttgc ggcacatgttgc tccctggccatc ggttgcgttgc ttttggatgttgc 360

5 gtatatgctg ggaacagggt gcaggggcc agcgttcctc cttcagccctt gacttggcc 420
 atgcacccccc tctcccccaa acacaaacaa gcacttctcc agtatggtc caggacagg 480
 gtcccttcag tcctctgggt atgacctaa gtcctacttg gcccctgcag cccagcctgt 540
 gtttaacct ctgcgtccctc aagaccacac ctggaagatt cttttccctt ttgaaggaga 600
 atcatcattt tgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgtttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgttag aaccacagg gcttcggccc agaccacagc gtcttgcct 780
 gagccttagag cagggatcc cgaattctg cattcaca cccacccatc aatttgtata 840
 accaaaggcc tcctgttctg ttatctact taaatcaaca tgcttattt ttttactca 900
 10 cttctgactt tagcctcggt ctgacccgt tatccatgca gtcatgtca cgtcttagtt 960
 acgtttttctt tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

 <210> 6
 <211> 2313
 <212> DNA
 15 <213> Human

 <400> 6

 20 ccagaggcagg cctgggtgtt agcaggacg gtgcacccgga cggccggatc gagcaaatgg 60
 gtctggccat ggagcacgga gggcttacg ctcggcggg gggcagctt cggggctgtc 120
 ggtattacct ggcgtacttc ttcccttcg tctccctcat ccaatttctt atcatcctgg 180
 ggctcggtctt cttcatggtc tatggcaacg tgacacgttag cacagagtcc aacctgcagg 240
 ccacccggcgc cggagccgag ggcctataca gtcagctctt aaggctcacg gcctccctgt 300
 ccaacttgcac caaggagctc aacttcacca cccgcgcacca ggtatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcac ctggaccgc tcaatgcccag ttccgcggc tgccagggtg 420
 accgggtcat ctacacaaac aatcagaggt acatggctgc catcatctt agtgagaagc 480
 25 atgcagaga tcaatttcaag gacatggaa agacgtgcga tgccctgtc ttcatgtca 540
 atcagaagggtt gaagacgtt gagggtggaa tagccaaggaa gaagaccatt tgcaactaagg 600
 ataaggaaag cgtgtctgtt aacaaacgcg tggcgaggaa acagctgtt gaatgcgtca 660
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720
 agccctctgc ctgccccctgg acaaggacaa gtttgagatg gacccctgtt acctgtggag 780
 ggactccat atccccacgca gcctggacaa cctgggttac aacccttacc atccccctggg 840
 30 ctcggatttgc cctccatcc gcagacccgtt cgaccacatg cccagcttca tgagctccaa 900
 gttggaggag ctggcccgga gcctccggc ggatatcgaa cgcgtggccc gcgagaactc 960
 agacctccaa cggcagaagc tggaaagccca gcagggccctg cggggccatgc aggaggcgaa 1020
 acagaagggtt gagaaggagg ctcaggcccg ggaggccaaatg ctccaaatgc aatgcctccg 1080
 gcagaccccgat ctgcgttgg aggagaaggc ggtgtctgcgg aaggaaacgag acaacctggc 1140
 caaggagctt gaaagaaaga agaggaggc ggagccatgc aggatggagc tggccatcatc 1200
 35 aaactcagcc ctggacacccat gcatcaagac caagtcgcgc cccatgttgc cagtgtcaag 1260
 gcccatgggc cctgtccca accccccatc catcgacca gctgttgcgg aggaggatcaa 1320
 gaggaagatc ctggagtccc agaggcccccc tgcaggatcc cctgttgcgg catccatgtt 1380
 ctgaggaggc tccaggcttgg aggaccaagg gatggcccgatc ctcggcggtt tgccggat 1440
 gcaggatgtt gctcacatgc cccgacacaa cccctcccg cccggccaa ccaccagg 1500
 ccaccatcatc acaactccatc gcatgaaac cccttagtacc ctctcacacc cgcaccccg 1560
 40 cctcacatgc ccttaccccg agcacacccgc cgcggagatg acgttcacgc agcaacggcg 1620
 ctgacgttcatc atatcaccgtt ggtgttggcg tcaatgttgcg atgtacatgc cacaaggaga 1680
 tatacgatgc gctgtgtca gatgcacgc gtcgcacaca gacatggggaa acttggcatg 1740
 acgtcacacc gagatgcacgc aacgacgtca cggggccatgtt cgcgttacatcataatg 1800
 tcacacagac gcggcgatgg catcacacag acgggtatgtt tgtcacacac agacacatgt 1860
 acaacacacaca ccatgacaaac gacacccatc gatatggcgc acacatcaca tgcacgcgt 1920
 cccttcaca cacaatctt acccaatttccatc cacttagtgc cactgttccccc cggccctggc 1980
 acacggggccca aggttacccac aggatcccat cccctcccgac acagccctgg gccccagcac 2040
 45 ctccccctctt ccagcttccctt ggcctcccg ccacttccctt acccccaatgtt cctggaccccg 2100
 gaggttggatc caggaagccca ttcacccctccg ctccttgcgtt gttgttgcgtt ccaggaccccg 2160
 ctggggccccc tgagccgggg gtgggggtca cttgttgcgtt ggagggggagc cactccctt 2220
 ccccaactc ccagccctgc ctgttggcccg ttgaaatgtt ggtggactt aataaatattt 2280
 50 agtaaatctt taaaaaaaaaaa aaaaaaaaaaaa aaa

 <210> 7
 <211> 389
 <212> DNA
 <213> Human

 55 <400> 7

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
 gccactggat tcatgtctag aaaagatagg ataatttctg taaaagaatg aagaccttgc 120
 5 tattctaaaa tcagatccctt acagatccag atttcaggaa acaaatacat aggggactaa 180
 ctttccttgt tcagattagt ttttctcctt tgcaccacgc tatataatat gaggaagtat 240
 tgacctttta aaagtgtttt agtttccat ttcttgata tgaaaagtaa tatttcggga 300
 gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggct 360
 tccttttgtg gtgtccagtg ggtaacatc

10 <210> 8
 <211> 157
 <212> DNA
 <213> Human

<400> 8

15 tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt gggtttgttag 60
 gaagcaggaa gcaagcccac tcaaacgtga aatttggcat gaggatcca gtaactttct 120
 cctcaatctg tgaactatata ttttttgc

20 <210> 9
 <211> 561
 <212> DNA
 <213> Human

<400> 9

25 aatagtcaaa acataaacaa aagctaattt actggcactg ttgtcacctg agactaagt 60
 gatgttggtg gctgacatac aggctcagcc agcagagaaa gaattctgaa ttccccttgc 120
 tgaactgaac tattctgtta catatggttt acaaattctgt gtgttatttc ttttctacct 180
 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tcatgtaaat 240
 tcctgatttt ttgcctgtt aatctctgtt gagctctact tttgtgtcatt caagatttt 300
 tgatgttggaa aggaaaatgt aatatgacat taaaatttgc tttttttttt gatgatagtc 360
 tcaccactat aaaactgtca attattgcatt aatgtttaag atatccatca ttgtgattaa 420
 30 ttaaacatcat aatggattt cttaatggag aattcttaat ggatggattt tccctgtatc 480
 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
 ctggcccaat ttcttagaaaa a

<210> 10
 <211> 1508
 35 <212> DNA
 <213> Human

<400> 10

40 cacaacacacg agagactcca cggctcgctt gaggccggcc agcctccctag gctccagcac 60
 tcgcagggtcc attcttctgc acggccctctt ctgtcccgat ccataagcac ggtcagctca 120
 ggggtcgccggaa gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
 ggatcatctt tctcctccgg gcctgtgtt gatggcataa tccgggtgca acccaaatct 240
 gagctcaaggc caggtgagct taagccactg agcaagggaa atttgggcctt gcacggccctac 300
 aggtgtgagg actgtgcacaa gtcaaatgtt aaggagtgc cctacccaaag gcctctgcca 360
 tcagactggaa tctgcgacataa gcagtgccctt tgctcgcccc agaacatgtat tgactatggg 420
 acttggtat gctgtgtgaa aggtctcttc tatcatgtt ctaatgtat tgaggacaac 480
 45 tggctgacaa accccatgttcc ttgcaggccatg tctctactgtt gatggcataatg gtcaggccatg 540
 ggtgtcatgtt ccctctttt gccttgcattt tggtgttacc ttccagccaa ggggtgcctt 600
 aaatttgcgc aggggtgtt tgaccgggtt aacaggctgtt gttgccgtt taaaactca 660
 aacacagttt gctgcaatgtt tccactgtc cccctcttgc accaacatag 720
 catcatatattt caggaatattt acagtaatgtt ggatttttt ttctttttt taatacataat 780
 atgcaaccaa ctaaacatgtt ataatcttgc cactgttataat agaaagtgtt gatagtctt 840
 50 gctgttgcg gtggaaatgtt ttttgcattt gtcggccatgtt aactgtatgtt cttttttttt 900
 ctcagctaat gggctcaaa gtatgatgtt cagaacttgc tgacccatgtt attgcataatg 960
 ctaaaagcaac acagacactc ctggccaaatg ttttgcattt tgaatgtatgtt ttgcacaaact 1020
 tgtaaatttag cagatgactt ttttgcattt ttttgcattt gtcggccatgtt aactgtatgtt 1080
 gtatatacaaa taatatttgc aactgtgaaa aacaagtgtt gtcacactac atggcacaga 1140
 55 cacaacatataat tataactaata ttttgcattt ttttgcattt gtcggccatgtt aactgtatgtt 1200
 ttagattgtt ttttgcattt cagaacggctt ttttgcattt gtcggccatgtt aactgtatgtt 1260
 ttcatgtata ttgtacatgtt acagtaatgtt tcaacccatgtt ttttgcattt ttttgcattt 1320

EP 1 166 798 A1

EP 1 166 798 A1

20 <210> 15
<211> 280
<212> DNA
<213> Human

<400> 15

30 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

35	ccccccgcag aactcccccc tggaaatagga tttttaaaaac ccttgacaat tagaaatcct 60 atagaggta gcattttta ggtaaaaata tggtgcccc tacagggatc atgcaacttc 120 cttaaaacca attcagcaca tatgtataaa gaacccttt taaaacatt tgtaactgaa 180 atacagacac agtgatgtg aagacactaa aaaaaactg aaaagtacta taccttgata 240 aattttgtt ttgcctttt tagagacttt ataattctta gtgttattt aaggacttga 300 atthaataat ggggttaatta cacaagacgt aaaggattt taaaaacaa gtattnnnn 360
40	ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420 aaaactgaag atagaccatt taaatgttc taccaaattt aacgcagcgtt aatttagggac 480 caggcacata ttttcttctg aacatttttgc tcaagcatg tctaaccata aaagcaaatg 540 gaattttaag aggtagattt ttttccatg atgcattttt ttaataaaatg tgcataagaaa 600 ataaaaacaa gcactgggt tggtctttt aagtataagg gtcataatgaa aaataaaaga 660 tagatattttt ttagatctg acattttaaac agtcatagta tttagacgtt cgtgaccagt 720 gcattttggta ctcttcaggc ataaaaatac gagttcgca actgtttaaa atcccttcctt 780 acccctcca ccagttggtc cacagcttc tgggggtcg ttgtcatcaa atccattggg 840 ccgaaatgaa catgaagcag atgcagctt gaggccccgg gtcgagcat tcaactttt 900 ttccctgtaaa tatagtttat tgcatttttgc tatagcatcc ataagttctt tctgttagagg 960 tgggtctcca tttatccaga gtccactgtt gggttttata ccaacttaaac catttagact 1020 atgcgtttt ttataaaaaa gcacataage tgcgttctt ggaacacgtc tcgttaattt 1080 ctggactgac tggaaatggaa taaatgtcact tctactgtca ttaaaaaaaa acccattttt 1140 ttgacatttc ttatttcc aaatcctgtt caaaaaactgc actgggacta tctctccctt 1200 gtaaatgact ctggggaggat gtaatgccca gagcctcaga ctgggtgtac atctgatatg 1260 aagagtctgt acttggatata ttctggcat aagaatagta atgcccactt tcagaggata 1320 taccagatgtt aaccacaacg gaaacttaata gataggcactt caattttgtt caggaagctt 1380 catcgttttttca tggaaatggttt aatttttttag caaggttctt actaagatca gtgaagtc 1440 catctacaga ccaactttctt gacaatggaa gaaaagaaatg aattttctca actggcaact 1500 ccaaaccacat tggccaggatca tacattgtct aaaaattttcc ttctccatgtt atacttctga 1560 tcatatgaaa atctcaggatca agttaagaata aggtattcag gttccctccgtt gatttgatca 1620
45	
50	
55	

EP 1 166 798 A1

5 gtttctcag cattttgcag agaggcacag ttttcacaat aatattgtt atcaccagta 1680
 agaatctctg gagcccaaaa aataatttg taagtcaagt actgaagggtg tggttcacc 1740
 tcccggttc tgaggtacat ctttattaac aagaatctt tagattcgt tagggacaga 1800
 agtggtttca gaacagtaaa actcatttagg aggactgcct atggttttt cattcacaag 1860
 tgagtcaacag atgaaggcag ctgttgttg attaaaaact actggcttctt ctgaaggacc 1920
 gggtacagac gtttgcatta gaccaccatc ttgtatactg ggtgatgtg ctggatctt 1980
 gagacatg ttttccaaag aagaggaagc aaaaaacgc agcgaaagat ctgtaaaggc 2040
 t
 10 <210> 17
 <211> 235
 <212> DNA
 <213> Human
 <400> 17
 15 cgccccggc aggtgtcagg gtttccaaac cagcctggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaattt aaaaattttag ccagggttgg cagcgaacaa ctgtagtc 120
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180
 tggccacga tcatgtcatt acactccacg ttgggtgaca aaatgagact gtcta
 20 <210> 18
 <211> 2732
 <212> DNA
 <213> Human
 <400> 18
 25 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag ctgtcgct 60
 tcatgttcat aactacttta tatggagtt cattggacct gtacccctca ttattctgt 120
 aaatattatc ttcttggtga tcacatttg caaaatggt aagcattcaa acactttgaa 180
 accagattct agcagggtgg aaaacattaa gtcttgggt cttggcgct tcgtctct 240
 gtgttcttgc ggccttcaccc ggtctttgg ttgtttt attaatgagg agatattgt 300
 gatggcatat ctcttcaacta tatttaatgc ttccaggga gtgttcattt tcattttca 360
 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggc ctcccaactg agagttccca cagttcgt aaggcatcaa ccaccagaac 480
 cagtgtcgc tatttcctctg gcacacagag tcgtataaga agaatgtgga atgatactgt 540
 gagaacacaa tcagaatctt cttttatctc aggtggacat aatagcactt caacactaa 600
 tcaaggtggc ataaaatctt atatattt acaggactga catcacatgg tctgagagcc 660
 catcttcaag atttatatca ttttagagac attcactgaa caatggccagg gatacaagtq 720
 ccatggatac tctaccgctt aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgca a gttgtggact gtggactaa tctgaatgtat actgctttt 840
 agaaaaatgt catttcagaa tttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgatc caccgttacca gtcaaaactcg tgatggagg tagcagcagt gaagatgtg 960
 ctattgtggc agatgttca tctttatgc acagcgcacaa cccagggtctg gagctccatc 1020
 acaaagaact cggggccac ttatttcctc agcggactca cttcccttgc taccacccc 1080
 agaagaaagt gaatgtccgag ggaactgaca gctatgttc ccaactgaca gcagaggctg 1140
 aagatcacct acagttcccc aacagagact ctctttatc aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccctgaca tggagaagaagc cctctctccc tccaggagga 1260
 gtgagaatga ggcacatttac tataaaagca tgccaaatct tgagctggc catcagcttc 1320
 agatgtgc ccaagatcgc a ggggcaata gtgatggta tataatcccc attaacaacaa 1380
 aagggttgtt tccagaagga gatgttagag aaggacaaat gcaactgtt acaactgtt 1440
 aatcatacag ctaaggaattt ccaaggccca catgcgatg ttaataaata aagacaccat 1500
 tggctgacg cagctccctc aaactctgt tgaagagatg actcttgc tgggttctc 1560
 tgggttaaaa aagatgactg aacccttgcag ttctgtgaat tttataaaa catacaaaaa 1620
 ctttgtatatac acacagatgt tactaaatgt aattattgt tacaagaaaa agagatgcca 1680
 gccaggattt ttaagatttc gctgtgtt agaaatgt tggaaacaagc aaaacaaaac 1740
 ttccagccca tttaactgcg cgcattgtg aactaaatgt taaaatatgg ctgcaccatt 1800
 ttttaggcc tgcattgtat tataataacg acgttgcatt taaaatctg tgggacacat 1860
 ttactgtacc ttactattcc tgacaagact tggaaaacgc ggagagatg tctgcattc 1920
 tttcagttc actgcaaatc ttatcatttgc aggcaaaatgt tggaaacatg cttaaccact 1980
 agcaatcaag ccacaggccct tatttcatat gtttcccaa ctgtacaatg aactatttc 2040
 atgaaaaatgt gctaaagaaaa ttatattttt ttctattgtt agggtaatattt aatacattt 2100
 gtgtcaactt gaaatataat tgcattttttt aataattttaa aggtgaaga aataatttgc 2160
 aaaaagctttt ggttgcacat gttatgaat ttttttttcc acactttgtc atggtaatgt 2220
 ctactcattt tcaacttctt tccactgtat acgttgcatt gctttgacaa agtttagtct 2280

ctggcttcc ttaatttaa gtcaagctt gcaatccctt cctcttaac taggcagggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c
 5 <210> 21
 <211> 179
 <212> DNA
 <213> Human
 10 <400> 21
 aggtgttaga tgctctgaa aaagaaaactg catctaagct gtcagaaaatg gattttta 60
 acaatcaact aaaggaactg agagaaaacct acaacacaca gcgttagcc cttgaacagc 120
 tttataagat caacgtgaca agtgtaaagg aattgtaaagg aaaaaattag aactaatgc
 15 <210> 22
 <211> 905
 <212> DNA
 <213> Human
 <400> 22
 20 tttttttttt ttcttaacc gtgtggctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaag gtccaaagcc ggctcaagaa 120
 ataaaaagggg aggtttggag taatagataa gatgactcca atactcaactt ttcctaaagg 180
 caaaggtaact tttgatagac agtctgatct ttgaaactgg tgaactccctt ttccacccat 240
 taccatagtt caaacaggca agttatggc tttaggagcac tttaaaattt gtggtggaa 300
 tagggtcatt aataactatg aatatatctt tttagaagggt accattttgc actttaaagg 360
 25 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 gggagctgga agagccttgg aagtttctat tacaaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctttt ttaactccat ctgtccagtg ttacaaaata aactcgcaag 540
 gtctgaccag ttcttgtaa caaaatatac tttgtgtgtc tttgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc ttccaaacat tgggggaaacc agtagaaaaaa 660
 30 ggcagggctc cctaattgtcc attattacat ttccattccg aatgccatgt gttaaaagt 720
 cctgaagatg gtaaccaggc tagtgaggaa taaatacccc accttgcaca gtccacagag 780
 aaacaacagt agaaaaggc ggcacttcc ttgtgtgtc cttttttcg 840
 ccatggattt cagtcctctc ctccagacca gctgttttattt tcctcagggg cccagggaaat 900
 gttga
 35 <210> 23
 <211> 2134
 <212> DNA
 <213> Human
 <400> 23
 40 ggtcttttctt ttccctttttt tttttccaaa agtgttcttt tatttcattt aacatataattt 60
 gtataaaatac tctattttat atgcaattcc acaaaaggcgataataattaa aagttttttt 120
 cattagaaaat aaatgtataa aaataaaatattt gtttattatg gcatttttata ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtattt tatagtaaaca 240
 tattttacta tatacatatg gaaaatatac tatttcatac gaaagactga acagacattc 300
 accaggatac gactgttggc ccagctgttcc gagatggacc tgcttccctt cagcagcctc 360
 45 cccaccacaa gacaaggatgat ctcaatgtcc ccaaaacctgtt gggaccctgt tctacacacc 420
 tcatttttgtt tccggcggtt catcccttcc ttgtgtattgtt actgattttc atgagacaca 480
 agttacttctt ttacatccat attccaaagg cagggttaca ttgttagggaa gaaagggagt 540
 tggaggtact aagtcattt ttttttttttccat agtcttacc agcatctaat gcttcactgc 600
 tttttttccat ttgttagactt taatgtactt gaataaaatac atggagttt tttttctca 660
 aatgaattt cacaataaaa gactgagatg gtcaaaaaaa gggaaaggaa agccatttgc 720
 50 gttatttcac gttgtggc cttttctca ttgtgtttttttaatttcttgc 780
 tagaaataat gtataaatac tctctgaaac catagcagcc ataaacagtg ctggtcaaag 840
 atccttattt tactcccttcc tccccccatt ttgtgtgttca taaatgtttttttaatgtttttt 900
 taaaatctca ctttttcttcc acttttccatt tcccaacccc catgataacta agtatttgc 960
 aagtaccagg aaacagggtt tgtaatagttt ctaactttttt ttgacaattt cttttttttt 1020
 tctaaacttgc taatgtatgtt aacaaaagaa ataataataa taatgtccccc ggcttttataa 1080
 55 tgcttatatca ctgctcagag gttataatac cttcaactt atcctatcaa atttgtcaact 1140
 ggcagtttac tctgtatgattt caactccctt tctatctacc cccataatcc caccttactg 1200

tat	tttataa	ggcccataaa	tactggtaa	actctgttaa	aagtgggc	tctatcttgg	420
at	gggttcac	tgccatcagc	catgctgata	tattagaaaat	ggcatcccta	tctacttact	480
tta	atgtctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgg	540
tc	agcccttc	catgtatcg	tttcaacttg	aatttgagac	caattaaatt	tcaactgtt	600
agg	gtggaga	aagaggtaact	ggaaaacatg	cagatgagga	tatctttat	gtgcaacagt	660
atc	cccttgca	tggggaggaga	gttactctt	aaaggcag	gcttaatgt	gacaatgtt	720
tgt	atatagt	tgagaattt	acgacactt	taaaaattgt	gtaatttgtt	aatgtccagt	780
ttt	gtctgt	tttgctgtt	gttttagtat	ttgtttctt	ggtggacc	tgaaaacc	840
acc	agttac	ggggagggtt	gatgtgtt	tcagggctt	ggatgtat	tggtttgt	900
tgt	attttcc	tccagagatt	ttgaacttt	ataattgcgt	gtgtgtttt	ttttttttaa	960
gtg	ggctt	tttttttct	caagtaaaat	tgtgaacata	tttcctttat	aggggcagg	1020
cat	gagtt	ggagactgaa	gagtattgt	gactgtacat	gtgcctt	aatgtttc	1080
tcg	acacatt	tttttcagt	aacttgaaaa	ttcaaaagg	acatttggtt	aggttactgt	1140
acat	caatct	atgcataaaat	ggcagctgt	tttcttgagc	cactgtctaa	attttgttt	1200
tat	agaat	tttttactgt	atgggttcat	agatggtcag	ttttgtacac	agactgaaca	1260
ata	cgact	ttggccaaaa	tgatgttagc	attgtttaa	cattgtgt	taacacctgt	1320
tct	ttgttaat	ttgggtgtgg	tgcatttgc	actacctg	gttacagtt	tcaatctgtc	1380
ag	taaaaataaa	gtgtccttta	acttcaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	

<210> 26

<211> 689

<212> DNA

<213> Human

<400> 26

```

aaacaaaaca aaaaaaaagg agtactgtat atgtaaaatac tagctttca atgtgctata 60
caaacaattt tagcacatcc ttccctttac tctgtctcac ctccctttagg ttagtacttc 120
ctttaataag tgctaaacat acatatacgg aacttgaag ctttggtag ccctgcctta 180
ggttaatcgc ctatgttaca ctgtttccag ggagtagttt aattactata aaccattatgc 240
cacttgtctc tgccacccattt atccacccagg gacagggtct ctcaaccttg gcgtactgt 300
catttggggc caggtgattt ttcccttgc aa gggctgtct gtacctgccc gggcgccgc 360
tcgaagcgtg gtcgcggccg agttactgaa aggaccaagg agctctggct gccctcagga 420
attccaaatg accgaaaggaa caaagcttca gggctctggg tggtgtctcc cactattcag 480
gagggtggcg gaggttaacgcg agcttcattt cgttccaggcc ttcccaagtat taaaaggtgt 540
tgtcaatagg ctgcattttt tcaggcaggat ctacaaaggc atccccaaagca tcaaacatgt 600
ctgtatgatgaa gtaatcaatg aaaaacccggaa acctccggacc acctccctgaa tagtggggaga 660
cacacccca ggcctgaaat ttcccttcg

```

<210> 27

<211> 471

<212> DNA

<213> Human

<400> 27

tccca	gcggc	atgaagttt	agattggcca	ggccctgtac	ctggggttca	tcccttcgt	60
ccctctcg	cattgggtgc	accctgttt	gcctgtctg	ccaggacgag	gcaaccctaca		120
agccctaacc	caggccccgc	ccaggccccac	cacgaccact	gcaaacacccg	cacctgccta		180
ccaggccac	gctgcctaca	aagaacaatcg	ggccccccta	gtgacactcg	ccaccacagc		240
gggttacaggc	tgaacgacta	cgtgtgagt	cccacaggt	gttttttttt	tggctgtctg		300
tgggctgg	cccgccggga	ctgtcaatgg	aggcaggggt	tccagcacaa	agtttacttc		360
tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgttctt	tagagcacag		420
ggacagaggg	ggaaataaga	ggaggagaaa	gctctata	ccaaagactg	a		

<210> 28

<211> 929

<212> DNA

<213> Human

<400> 28

```
ggtaactca gtgcattggg ccatgttc gacacaggt ctgccagcca caaccatct 60  
gtctttcttc acggtttggc tctgttgaaa ctttcccccc actgttcattt ggacatctt 120  
tggaaagaac aacgcgcaggcc cctttgtatgc accctgttcgg actaaagaaca tcgccccggga 180  
gattccaccc cagcccttggt acaaagtctac tgtcatccac atgactgttg gaggettc 240
```

gccttcgt	gccatctcg	tggagctgta	ctacatctt	gccacagtat	ggggtcggga	300
gcagtagact	ttgtacggca	tcctcttctt	tgttccgc	atccctgctga	gtgtggggc	360
ttgcatctcc	attgcactca	cctacttcca	gttgctggg	gaggattacc	gtctgggtgt	420
gcatgttgt	ctgatgttg	gtccacccgg	cctcttcat	ttccctact	cagttttcta	480
ttatggccc	cgctccaaaca	tgtctggggc	agtagacaga	tgatgttct	tcggctactc	540
cttactcact	ggttatgtct	tcttcctcat	gtctggcacc	atccctttt	tttcttcctt	600
aaagttcatc	cggtatatatct	atgttaacct	caagatggac	tgatgtctgt	atggcagaac	660
tattgtcttt	ctctccctt	cttcatgccc	tgttgaactc	tcctaccagc	ttctcttctg	720
attgactgaa	ttgtgtatgc	gtatgttgc	cttcccttt	tcccttggg	cattccttcc	780
ccagagaggg	cctggaaatt	ataatatctt	atcacataag	gattatatat	ttaaactttt	840
taatggcc	ttatgttgg	tcctgatttt	tcttttaca	attacaaaaa	taaaaatttat	900
taagaaaaaaq	aaaaaaaaaa	aaaaaaaaaa				

<210> 29
<211> 1775
<212> DNA
<213> Human

<400> 29

gaacgtgtat	ggaactttgg	gaggatgtct	gaaaaaatgt	ccgaagggtat	tttggccaac	60
accagaaaac	gc当地tgc当地	taggattcc	ctcccaaat	gttcccaaa	aaattactca	120
ttgacaattc	aaattgcact	t当地tggc当地	cagcccggc	ggecttc当地	c当地gtt当地	180
c当地cccgctg	gc当地ttctct	c当地taggactc	cccaaactcg	ttcactctgc	gtt当地tatccac	240
aggataaagc	c当地ccgtgt	acaggatagac	c当地agaaacacc	acgtc当地tcc	ggaagcaggc	300
c当地ccggta	gac当地tgggca	t当地gtatgtat	gaaggcaaaag	acgtcatcaa	t当地aagggtt当地	360
gaaagcttct	taggtaagg	c当地tccaggg	c当地atgtgcc	actgacttca	actt当地gtatgtt	420
c当地aaagac	t当地gggc当地	t当地aaagaggaa	acccaaaggac	tagaccctgt	tgacacaagact	480
gtt当地attaac	c当地aggatacc	agcttctata	ttt当地gatattc	aggagt当地aat	agacagcacc	540
cccgacacag	agagggtaca	gcaaggatata	caagtaacttc	atggc当地ttag	tatcgtactc	600
ctcggtttc	ctctc当地agatt	c当地gtatgt	gccaaactga	aattc当地gggca	tc当地aggctct	660
c当地aaaaata	gtc当地atcttca	atgc当地tcttt	cacttccac	agctcaatgg	c当地ggcttcaac	720
acccggccgg	accagcacca	gcaaggctc当地	ctgctc当地gtcc	agc当地agaaca	gaaagatgac	780
c当地cggtgc	aagc当地gc当地	agagcactgc	ttt当地gggac	atgc当地gatca	t当地gtt当地ttt	840
ctt当地tccag	aaactgatgt	c当地tttttaaa	ggccaggaaa	t当地aaagagaa	gatggaacgc	900
t当地cgacaaa	aaggtc当地agcg	ccaggaaagta	taagttgta	t当地tacaaaaa	ttc当地tccat	960
ctcatc当地ga	tctt当地tctg	aaaacc当地cgaa	ctgctc当地gagg	gagtaacacgg	c当地gtctgcat	1020
gtggatccag	aagc当地c当地gagcc	gccccagtg	gacctt当地gtcg	taggacacgg	tgaggggca	1080
ctcggtgg	gagc当地gttta	t当地gaccatc当地	gtc当地cttca	cggt当地gtcg	gctt当地gtcat	1140
gaacaggatg	ggc当地ggtaat	gcaagggttt	ccccagctgg	atc当地atcttca	t当地gtaccatg	1200
c当地atcg	ggcaggagg	acc当地gtt当地aaa	gacaaggatg	tccgc当地atca	c当地gtt当地cgc	1260
c当地ggcggt	c当地ccagtg	gactt当地ggctc	atccaggac	ctc当地gtcg	t当地tttccgc	1320
ctcgatctc	t当地gtatcg	acttccccc当地gt	gagcagggt	attt当地tttctg	gctt当地gggac	1380
catgttaggt	gtc当地aggagac	t当地gaccagg	cacctgctc	ccgtc当地gtcc	acggcaggac	1440
ccc当地agctg	t当地ggagaaga	t当地taggc当地ata	cagcgtccca	ttgtt当地tctg	ttt当地tttgg	1500
taacagaaaaca	ttaactgtcc	ttt当地caattt	ggacttccaca	t当地aaagatgtt	ccacattca	1560
gaccaggatc	atgtt当地tct	c当地gaccacc	gtt当地ggac	gtc当地gtt当地gt	acacgctc当地	1620
ctcgactt	ggc当地ccgc当地	c当地aggatagg	ctggatc当地ag	ttggc当地tctc	c当地ggagcacc	1680
gccccgggtt	acgatc当地ccgt	acatgaccca	cgaggatgtc	accacgt	tgacacaac	1740
gccccacc	aagctgtq	aggagctq	cccc			

<210> 30
<211> 1546
<212> DNA
<213> Human

<400> 30

aaaataagta ggaatgggca gtgggtattc acattcacta cacctttcc atttgctaat 60

aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120
acaccatcta	cgggcaccat	ggaactgctt	caagtgcacca	ttcttttct	tctgcccagt	180
atttcagca	gtAACAGCAC	aggtgtttta	gaggcagcta	ataatcact	tgttgttact	240
acaacaaaac	catctataac	aacacccaaac	acagaatcat	tacagaaaaa	tgtgtcaca	300
ccaacactg	gaacaactcc	taaaggaaaca	atccaatcgt	aattacttaa	aatgtctctg	360
atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgtat	420

5 aaatctgtcc ttttttgtac caaacctgag gtcttttgg a gataatgt a gaaaaccact 1140
 acctattgaa ggcctgttt ggcta atctg tgcaaaactct gatgataacct gcttatgtgg 1200
 attctttcc acactgtttt catttttaag tataaagact tagaaaacta gaataatgt 1260
 tttacaata attaaaaga t tgatgttc tgggtttt cttctttt agaaccctgt 1320
 atttaaacaac gccttcttt taagtcttg ttgaaat tttt a gtcctcgat ctctggata 1380
 ccaaatac aacccaaacgc gtaaaacagg cgat tttt gttccataat tttaaaaagc 1440
 tttatgtata ctctataaat atagatgt aaacaacact tccccttgg tagcacatca 1500
 acatacagca ttgtacatta caatggaaat gtgtactt a ggttattat atatataaat 1560
 acatatataac ttgttaacc ttataactgt aaataaaaaa gttgttttag tc aaaaaaaa 1620
 10 <210> 33
 <211> 2968
 <212> DNA
 <213> Human
 15 <400> 33
 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 gaggaggaag aagaggaa a gaaatgtaa gaaatgtgg aggaggagg a gaggaggga 120
 gaaatgtgg gca gatgtgg a gatgggg a gatgggg a gatgggg a gatgggg 180
 gggaaagacat tagataaaaaa gccaatgtaa gaaatgtgg cagattctga atatgtact 240
 gatgtgtatc ggactaaaga agaaagggt tatgacaaag caaaacggag gattggaaa 300
 cggcgacttg aacatagtaa aaatgtaaac accggaaaacg taagagcccc tattatctgc 360
 gtacttgggc atgtggacac agggaaagaca aaaattctag ataagctccg tcacacacat 420
 gtacaatgt gtggcagg tggatcaca caacaaatgg gggccacca tggatcataat 480
 gaagcttata atgaaacacgac taatgtgg aaaaatgg atagagagaa tggatcggatt 540
 ccaggaaatgc taattatgtg tactctggg catgaatctt tcgatatact gagaataga 600
 ggaagctctc ttgtgacat tgccattttt gttgtgata ttatgtatgg tttggagccc 660
 cagacaattt agtctatcaa cttctcaaa tctaaaaat gtccttcat tggatcactc 720
 aataagattt ataggatata tgattggaa aagatgtgg actctgtatgt ggctgtact 780
 ttaaagaagc agaaaaagaa tacaaaatgt gatgggggg a gcttattt 840
 gtatgttgc acaggcagg tttgatgt gctttttt atgatgttgc agatccccgc 900
 acttggatgt ctggatgtc tacatgtgc catactgtg atggatggg a gtcgtatc 960
 20 tacttcttg tagatgttac tcagggatc ttgagcaag a gtttgcaca ctgtgaaagag 1020
 ctgagagcac aggtgttgc ggttaaagct ctccgggg tggcaccac tataatgtc 1080
 atcttgcata atggcggtt gaaaggaa gatataatca ttgttcttg agtataaggg 1140
 cccattgtaa ctcagattcg aggccctctg ttacctctc ctatgtggg attacgtgt 1200
 aagaaccatg atgaaagca taaaatgt gaaatgtggc agggggtaa gattttgg 1260
 aaagacctgg agaaaaacatt ggctgggtaa cccctcttgg tggctttaa agaagatgaa 1320
 25 atccctgttca ttaaagatgtt atgttccat gatgtttttt agacactaa tgctatcaaa 1380
 ttgaaagaaa aaggatgtca tggcaggca tctacactgg gtttttgg agtctactg 1440
 gaatttctga aaacatcaga agtgcctat gcaatgggaa acattggccc agtgcataaa 1500
 aaagatgtt gaaaggcttc agtgtatgtt gaaatgtgg ctcgtatgc agtataatgg 1560
 gccttcgtatc tgatgttgc acggatgtca caagaaatgg ctgtatgtt aggatgtt 1620
 atttttatgtt cagaaatgtt ttatgtatgg ttatgtatgg tttatgtatgg 1680
 tacaagaaac agaaacaaaga agatgttgc acatgtgg ttttccatgg caagataaaa 1740
 30 atccctccctc agtacatgtt taatgtatgg gatccgtatc tgatgtggg gacgtggaa 1800
 gcaggttcagg tggaaacagg gacacccatg tggatccaa gcaaaaatgg tggatcactc 1860
 ggaatgttca caagtatgtt aataaaccat aacaatgtgg atgttgcata aaaaaggacaa 1920
 gaaatgttgc taaaatgtt acctatccct ggtgtatgtc ccaaaaatgtt tggatcact 1980
 ttgtatgttca cagatgttgc tgatgtatgtt acatgtggc agtccatgtc tgcactcaaa 2040
 gactgttca gatgtatgtt gcaatgtgg gactgtggc gtttggatgtt gctgtggaaa 2100
 35 gtatgtatgttca tcatctatgtt ttttcatgt gcaatgtgg gacgtggatgtt gcaatgtgg 2160
 gttgtatgttcccaatccatgtt gcaatgtgg gacgtggatgtt gacactgtatgtt 2220
 gacttataatgtt gcaatgtgg gacgtggatgtt gtttccatgtt gcaatgtgg 2280
 aacttataatgtt gcaatgtgg gacgtggatgtt gtttccatgtt gcaatgtgg 2340
 actcaccttc cccttccatgtt accttgcgtc tgatgtatgtt gtttccatgtt 2400
 cccaaatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2460
 40 gtactgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2520
 acgtatgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2580
 tctgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2640
 agctgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2700
 agtcacgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2760
 45 catccatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2820
 agttgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2880
 ggtatgtatgtt gatgtatgtt acatgtatgtt gtttccatgtt gtttccatgtt 2940

tgatcggttt agtagagatt ttatacat

<210> 34

<211> 6011

<212> DNA

<213> Human

<400> 34

10

acggggcgcg ggacgacccg cacatcttat cctccacgcc ccactcgcac tcggagcggg 60
 accgcggccg actccccctc gggccggcca ctgcaggagt gaggagagag gcccggcc 120
 cggcttgacg cgagcgcagc accccccggc ccccgccca gaagtttggt tgaaccgggc 180
 tgccggaga aacttttttc tttttccccc ctctcccggtt agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctgcgggctt cggggtcgcg cggccgcaga agggcgggg 300
 tccggcccg aggggaggcg ccccccggga cccgagaggg gggtgaggac cgcgggctgc 360
 tggtgccggc gcgccagcgt gtcccccgcg caggggaggc gccgccccgc tccggcccg 420
 gctgcgagga ggaggcggcg gccgcgcagg aggtatgtact tggtggccgg ggacaggggg 480
 ttggccggct gccggcacct cctgtctcg ctgtctgggc tgctgtctg gccggcgc 540
 tccggcacc cggcgcttgtt ctgcctgcct tggtaacgtt ccaagtgcga ggagcccaagg 600
 aaccggcccg ggacgatctgt gcaggcgctc tgccgtctgt gctacacgtg cgcggccag 660
 gggaaacgaga gctgcggcg cacccctcggtt atttaacggaa cctgcgaccg ggggtcgct 720
 tggtcatcc gccccccgct caatggcgac tccctcaccg agtacgaagc gggcgttgc 780
 gaagatgaga actggactga tgaccaactg cttgggttta aaccatgaa tgaaaacctt 840
 attgtctggct gcaatataat caatggaaa tggtaatgtt acaccatcg aacctgcagc 900
 aatccctttt agtttcaag tcaggatatg tgcccttcag cttaaaagaa aatttaagaa 960
 gagaagccag attgtcccaa ggcccgtgtt gaaatccatgt tcttcacacg ttgtccctgaa 1020
 gattctgttc tgatcgaggg ttatgtctt cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtca acccccgagg ctgtctgcgc aaagtctgcg agccggggaa cctgaacata 1140
 ctatgtctaa aaggcctcagg gaagccggga gagggtctgtt acctctatgtg tgcaaaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcaacgtac cgcgtgtccc 1260
 ccggacagact atgaaatcta agtcagacta actgcagatg gttgctgtac tttgccaaca 1320
 agatgcgagt gtctctgtt cttatgtgtt tcccccgtgtt gtaggggtggg atccactcc 1380
 cgcatagtc ctgcgtggcg tgggacacccat gaaatgtgtt gtatgtctt taaatgttt 1440
 aatgatacaa agccagccgt cgtatataac aatgtggaaat attatgtatgg agacatgtt 1500
 cgaatggaca actgtcggtt ctgcgtatgc caagggggcg ttgcacatctg cttcaccggc 1560
 cagtgtgggtt agataaaactg cgagaggatc tacgtgcgg aaggagatgt ctgcggactg 1620
 tggtaatgcgatc ttttataat cccgtcggtt gctatgcac tggctgtatc 1680
 cttggccacac gagaccgggtt gcgccggagac gactgcacatc tctgcgtatc cgtcaacccgt 1740
 gaacggccact cgcttcgcac tctgcgcgca cagacgtca caaacccgtt gaaatgtcc 1800
 ggggagtttat caaaactgcac tctgacacgg aaggactgca taaatgtttt caaacccgtat 1860
 cacaatgggtt gtcggacactg tcagtgcata aacaccagg aactatgtt agaacgtaaa 1920
 caaggctgcac cttgtactg tcccttcgtt ttcctactgt atgcccggaa ctgtgagatc 1980
 tggtagtgcg gcccggccca caaaggatgc agaccatcaa tctgtgacaa gtatgtcca 2040
 cttggattgc tgaagaaataa gcaacgtgtt gacatgttgc gctgtaaaggaa atgtcccgag 2100
 ctctcatgc gtaagatctg ccccttgggtt ttccagcagg acatgtatc ctgtcttatac 2160
 tgcaagtgcg gagaggcctc tgcttcagctt gggccaccca tcctgtccggg cacttgtctc 2220
 accgtggatg gtcatcatca taaaaaatggag gagagctggc acgtatgggtt ccggaaatgc 2280
 tactgtctca atggacggga aatgtgtgcc ctgtatcacct gcccgggtgcc tgcctgtggc 2340
 aaccggccacca ttccatctgg acatgtgtc ccatcatgtg cagatgactt tgggtgcag 2400
 aagccggccatc tcgtactcc ctccatttgc cagccggccgtt gaggagaata ctttggggaa 2460
 ggagaaacgtt ggaacatgtt ctcctgtactt cgtgcacccat gccacagccg acgggtgtctg 2520
 tggtagacatc aggtgtgcgg accgtgtctc tgccagaaacc cctcgtatgc ccaggattcc 2580
 tgctgcccac agtgtacaga tcaacccctt cggcccttctt tgccctggaa taacacgtt 2640
 cctaattactt gcaaaaatgtt tgaagggtt atattctgg cagctgtatc ctggaaaggcc 2700
 gacggttggta ccacgtgcat ctgcattgtt acgtatgtt gctgtttctc tgatgtctgc 2760
 cttctgtat cctgtgaaatg acctgtcttggt agaaaaggcc acgtgttgcctt ctactgtatca 2820
 aaagacacaaat ttccaaatggaaat ggtgtgtgc cacttcgtt ggaaggccat tgccgacgag 2880
 gagcggtggg accttgacacat ctgcacccacat tgctactgtcc tgcaggccca gaccctctgc 2940
 tcgaccgtca gctggccccc tctggccctgtt gttgagccca tcaacgttgc aggaagttgc 3000
 tgcccaatgtt gtcacaaatgtt gtagtgcataa gaaatccat atataccat tgagaagaca 3060
 aaccatcgatc gagagggttgc cctggagggtt cccctgtggc ccacgcctat tgaaaatgtat 3120
 atcgccatc tcccttagaga tatgggtcac ctccaggtat attacagaga taacaggctg 3180
 55

5	caccgaatgt aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300 tgcctctcta ttataatagc attccttattc atcaatcaga agaaacagtg gataccactg 3360 ctttgctggt atcgaacacc aactaaggct tcttccttaa ataatcagct agtatctgt 3420 gactgcaaga aaggAACCCAG agtccagggt gacagttccc agagaatgct aagaattgca 3480 gaaccAGATG caagattcag tggcttctac agcatgcaaa aacAGAAACCCA tctacagcg 3540 gacaatttct accaaaACGT gtgaagaaAG gcaacttagg tgaggTTTCa aaAGACGGA 3600 gacgactaaAA tctgctctaa aagataaAGT agaatttGCTCAGTCTG ttggattgt 3660 ttggattgtg acttgatgtc cagcgctaaG accttactgg gatgggTCCTCtgcatacagc 3720 atgtgcagaa caagcattcc cacttttctt caagataact gaccaAGTGT tttcttagaa 3780 ccaaAGTTT taaaAGTTGCT aagatataatt tgcctgtaaG atagctgtAG agatatttGG 3840 ggtggggaca gtgaggTTGG atggggAAAG gggTgggAGG gttgggttgg gaagaaaaAT 3900 tggcagctt ggcTCGGGGa gaaACCTGTG aacataAAAG cagtTCAGTG gcccAGAGGT 3960 tatttttctt ctattgCTCTTt gaagactgca ctgggtGCTG caaAGCTCAG gctcgtatga 4020 gcagAGAAACA aaaaAGGCCt gtcgaccCAG ctgcCATAAC caccTTGAGA ctaccAGAC 4080 agcacatcag aaccCTTGA cagccatccc aggtctAAAG ccacaAGTTT ctttctcta 4140 cagtccaaAC tgcagttagc aagtggAAAG ccagAGAAAT gcgatAGCGG catttctcta 4200 aagcgggttca ttaaggatata atacagttac acttttGCT GCTTTATTt tcttccaAGC 4260 caaatcaatcA gccAGTTCTTt agcagAGTCa gcacatgaaAC aagatctaAG tcatttcttg 4320 atgtgagcac tggAGCTTTT ttttttaca acgtgacAGG aagaggAGGG agaggGTGAC 4380 gaacACAGG CATTTCAGG ggctatTTTt cactgtttGTTGCTTtG ttgttGTTt 4440 ttgttGTTG ttcatAGTTT gactgtttGG ggattctttt tccttattt atactgattc tacAAAATAG tttttaaaaA 4500 attttaatttG tatatttttca aagcaccttG gttgaagCTC aaaaaaaaaAtG aaactacttC 4560 aaactttAGC aattatAGGA gtatTTATGT aactatCTTA tgcttcaAAA aacaaaAGTA 4680 tttgTGTGCA tggTgtatata atatatataAT atacatataAttatACAC atacaatTTA 4740 tggTTTCTG tggtaatgtat tttttagAGA tttaaccAG aacAAAGGCa gataAAACAGG 4800 cattccatAG cagtGCTTTTt gatcaCTTt aatTTTTG aataacacAA aatctcatTC 4860 tacctgcAGT ttaattggAA agatgtgtG gtgagAGTAT gtatgtgtGt gtgtgtgt 4920 gtgtgtgcG ggcgcacgcac gccttgAGCA gtcagcattG cacctgttatG ggagaAGGGT 4980 attccTTTAT taaaatCTTC ctcatTTGGA tttgttttca gttggTTTtC aatttgcTCA 5040 ctggccAGAG acattgatgg cagttcttAT ctgcatcaCT aatcagCTCC tggatTTTT 5100 ttttttttca aacaACATG gttgaaACAc actatggAA tattgtccAC aataAGCTGG 5160 aagtTTGTTG tagtATGCT caaaataAC tgactgtata ctatagtGTT aacttttCAA 5220 acagccCTTA gcaCTTTTt actaattAAAC ccatttGTC attaggtttt CTTTTTAAA 5280 tgcttGTTGt gaaaAGACACA gataccAGT atgcttaACG tggAAAAGAAA atgtgttCTG 5340 ttttgtAAAG gaaACTTCAA gtattgtgt AAATAACTTGG acagaggTTG ctgaacttA 5400 aaaaAAATTA atttatttatt ataatgacCT aatttattAA tctgaAGATT aaccattttt 5460 ttgttCTTAGA atatcaAAAAA gaaaaAGAAA aagggttCTC atgtgtttGc atcaaAGGAA 5520 aaaaAGATTt attatCACAGG ggcaatTTTt ttatTTTCAAA aaaaATTAAT ttgttAATGA 5580 tacattacAA aataAGATG acatcAGGCT ttagattata aattttGTTG gtaattaATC 5640 cattcCTGGC ataaaaAGTC ttatCCTAA AAAATTGTTAG gatcttGCTTttttttt 5700 caatcatGGC catattatGA aaataACTAAC aggatataGG acaAGGTGA aattttttta 5760 ttatttatttAA aagatATGA ttatCCTGA gtcgtgtatC tattactCTT ttactttGt 5820 tcctgttGtG ctcttGtAAAG aaaaaAAAT AATTCTCTGA agaataAAAT agatataTGG 5880 caactggAGt gcatcatAGT tctacAGTTt gtttttttGTTT tcttcaAAAAA agctgtAAGA 5940 gaattatCTG caacttGTTt ctggcAGGA aataaacatt ttgagttGAA atcaaaaaAA 6000
10	
15	
20	
25	
30	
35	
40	

<210> 34a
<211> 1036
<212> DNA

45 <213> Human
<400> 34a

<400> 34a

50	mylvagdrgl agcghllvsl lgllllpars gtralvcplc deskceeprn rpgsivqgvc 60 gccytcasqq nescggtfqi ygtcdrglrc virpplingds lteyeagvcl denwtddqil 120 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180 vqfspsrcped svliegyapp geccpplsra vcnpagclrk vcqpgnlnil vskasgkpe 240 ccdryeckpv fgvdcrtvec ptvqqtacpp dsyetqvrlt adgcctlptr ceclsglcgf 300 pvcevgstpr ivsrgdgtpg kccdfvcfn dtkpacfvnn veyydgdmfr mdnncrfcrq 360 ggvaicftaq cgeincerry vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420 ctfcqcvngc rhcavatvcqg tcttnpkvpg eccpcept iitvdppacg elsnslttrk 480 dcingfkrdh ncgrtcqcin tqelcserkq gtlncpfgf ltdaqnceic ecrprpkkr 540
55	

EP 1 166 798 A1

piicdkycpl gllknkhgcd icrckkcpel scskicplgf qqdshgclic kcreasasag 600
ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
5 qnpsrtqdsc cpqctdqfr pslsrrnnsvp nyckndegdi flaaeswkd vctscicids 780
viscfsescp svscerpvr kgqcpcycik dtipkkvvch fsgkayadee rwldsdcthc 840
yclqqqlc tvscpplpvc epinvegspe pmcpemvype ptnipiektn hrgevdlevp 900
lwptpsendi vhlpdmglh qvdyrdnrlh psedssldsi asvvvpiii lsiliaflfi 960
nqkkqwipll cwyrtptkps slnnqlvsd ckkqtrqvds ssqrmlriae pdarfsgfys 1020
mqkqnhlqad nfyqtv

10 <210> 35
<211> 716
<212> DNA
<213> Human

15 <400> 35

gcagtacctg gagtgtcctg caggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
acccggggct cctggggcgc tctgggggc tggggctgag cagcgatct cttttgtccc 120
20 agaagtccag agggatcagc cccagaacac accctctcc cccggacgcc gcagcttct 180
ggaggcttag gaaggcatga agagtggct ccacctgctg gccgactgag aaaagaattt 240
ccagaactcg gtccttatcc acagatttagg aaactatggt tcaagaagag aggacggggc 300
ttgagggaat ctccatgtt tccttatatg acctcaaact gaccatacta aacagtgttag 360
aaggctctta taaggctcta aatgtcaggg tctccatcc cctgatgctt gacttgcaca 420
25 gtcagtgtgg agtagacggg ttccctccacc cagggttgac tcagggggat gatctgggtc 480
ccattctgtt cttaaagaccc caaacaaggg tttttcagc tccaggatct ggagcctcta 540
tctggtagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600
cccccatcca cctaaacaggg tggcacagg gattactgag ggttaagacc ttagaactgg 660
gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaaa aaaaaaa

30 <210> 36
<211> 395
<212> DNA
<213> Human

<400> 36

ccaataacttc atttttcatt ggtggagaag attgttagact tctaaggcatt ttccaaataa 60
aaaagctatg atttgatttc caactttaa acattgcatt tcctttgcctttactacat 120
tctccaaaaa aaccttggaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
atgattatta cattggaaatc cttagccta tgtagatattt cttaactt gcactttcac 240
35 gcccagtaaa accaaagtca ggtaaccaa tgtagatccaaatgtta aaaccttaat 300
tgcaagtccct tttttaaattt atttaaaga ttacttaaca acatttagaca gtgcaaaaaa 360
agaagcaagg aaagcatctt taattctacc atcct

40 <210> 37
<211> 134
<212> DNA
<213> Human

<400> 37

ccctcgagcg gcccgggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
aaccctataaa gctgcctggc tttcagcaac aggctatca acaccatggt gatctccat 120
aagggacacc gtgt

45 <210> 38
<211> 644
<212> DNA
<213> Human

<400> 38

aagcctgttgc tcatggggaa ggtggtggcg ctgtgtggcc actggcgcc gaggttagagg 60

<400> 41

aacagagact	ggcacaggac	cttccattt	caggaatgt	gtatgttagg	caggttaacat	60
tgagctttt	tcaaaaaagg	agagcttc	ttcaagataa	ggaagtggta	gttatggtgg	120
taaccccccgg	ctatcagtcc	ggatggttgc	caccctct	gctgttaggt	gaaaggcagcc	180
atggagtggg	agggaggcgc	aataagacac	ccctccacag	agcttggcat	catgggaagc	240
tggttctacc	tcttcctggc	tctttttttt	aaaggccttg	ctgggagcct	tcctttttggg	300
tgtcttttctc	tttccaacc	aacagaaaaag	actgtcttc	aaagggtggag	ggtcttcatg	360
aaacacagct	ggcaggagcc	caggccacagg	gctggggggcc	tggaaaaaaaagg	aggccacaca	420
ggaggaggga	ggagctggta	gggagatgt	ggcttttacct	aaggctctcgaa	aacaaggagg	480
gcagaatagg	cagaggcctc	tccgtccccag	gccccatttt	gacagatggc	gggacggaaa	540
tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtgg	tgccgggtg	600
gaacaaggcac	aggccttgg	atccaatgg	ctgaatcaga	acccttagggc	tgcctatctgt	660
cagccgggtg	acctgggtca	attttagct	ctaaaagcct	cagtctccctt	atctgcaaaa	720
tgaggcttgt	gataccgtt	ttaaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
aataatctac	ggccatacca	ccctgaacgt	gcttaatctc	gtaagcttaag	cagggttcagg	840
cctgggttagt	acctggatgg	ggagagatgt	gaaaacatac	ctgcccccgag	ttggagttgg	900
actctgtctt	aacagtagcg	tggcacacag	aaggcactca	gttaataactt	gttgaataaaa	960
tgaagtagcg	atttgggtgt	aaaaaaaa				

<210> 42

<211> 956

<212> DNA

<213> Human

<400> 42

cggacggtgg	ggcggacgcg	tgggtgcagg	agcaggccgg	ctgccactg	ccccaaaccaa	60
ggaaggagcc	cctgagtcgg	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
ttgcctgtct	aaagccttaa	ctaagactcc	cggcccgggc	tggccctgt	cagaccttac	180
tcaggggttg	tttacactgtt	gctcgggaa	ggagggaaag	ggggggggga	ggggggcacgg	240
caggcggtgg	gcagccacac	gcaggcgccc	aggggccgca	gggacccaaa	gcaggatgac	300
cacgcaccc	cacgcactg	cctcccccgaa	atgcatttgg	aaccaaagt	taaactgagc	360
tcgcagcccc	cgcgcctcc	ctccgcctcc	catcccgctt	agcgctctgg	acagatggac	420
gcaggccctg	tccagcccc	agtgcgtcg	ttccggtccc	cacagactgc	cccagccaac	480
gagattgtcg	gaaaccaaagt	caggccagg	ggcggacaa	aaggccagg	tgcggccctgg	540
ggggaaacgga	tgctccgagg	actggactgt	tttttacaca	catcggtgcc	gcagcggtgg	600
gaaggaaaagg	cagatgtaaa	tgatgtgttgc	gtttacagg	tatatttttg	ataacctcaa	660
tgaattaat	cagatgtttt	acgcgaaggaa	ggacttaccc	agtattactg	ctgtgtgt	720
tttgatctct	gcttaccgtt	caagaggcg	gtgcaggccg	acagtccgtt	acccatcac	780
tcgcaggacc	aaggggccgg	ggactgtctgg	cctacggccc	gctgtgtctt	ccctccccctc	840
ccttccttgg	gcagaatgaa	ttcgatgcgt	attctgtg	cgccatctgc	gcagggttgt	900
ggtattctgt	catttacaca	cgtcgttctaa	attaaaaaagc	gaattataact	ccaaaaa	

<210> 43

<211> 536

<212> DNA

<213> Human

<400> 43

```

aaataaaacac ttccataaca tttgttttc gaagtctatt aatgcatacc cacttttcc 60
cccctagtt ctaaaatgtt aaagaggggg aaaaaggct caggatagtt ttccatctac 120
agtgttagt gtctttttttaa ttactcttgg aataagagac tcctataggg ttttgatcatc 180
ttggaaaccc agttttacca ttgtgtcagt aaaacaataaa gatagttga gagcatatga 240
tctaaataaa gacatttcaa gggttagttt gaattctaaa agtagtaat accaaatag 300
cattctcatc ccttaacaga caaaaacttca ttgtcaaaa gaatttagaaa aggtgaaaat 360
atttttccca gatgaaactt gtgccacttc caattgtacta atgaaataaca aggagacaga 420
ctggaaaaaa tggttgtatgc cacctttttaa accttttctg gtaaatatta tggtagctaa 480
agggtggttt ccccgccacc tgacacttga caggtaggtt tccgtggta accagt

```

<210> 44

<211> 1630

<212> DNA

<213> Human

<400> 44

```

ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctccctggg caccaagtcc cagggcaggag cagctgttt ccatcccttc ccagacaagc 120
tctatttttt tcacaatgac cttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctcg gaggaaagag gcaggaaaaat tctcccccggg tccctgtcat gctactttct 240
ccatcccaagt tcagactgtc caggacatct tatctgcaga ctaaagagaa ttataaggca 300
gtgattccc ttagggccag gacttgggcc tccagctcat ctgttccctc tggggccatt 360
catggcaggt tctgggctca aagctgaact ggggagagaaa gagatacaga gcttacatgt 420
gactttacct gattgccctc agtttggggt tgcttatttg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattt gtcagatga cccctgagggg ctcttccca gttgaaatgc attccatgtat 600
attaggaagt cgggggtggg ttgtgtgtgt gggcttagtgc gggtttqaatt tagggggccga 660
tgagcttggg tacgtgagca ggtgttaaag tttaggtctc ctgttatttc tggtccccc 720
gaaaatgttc ccttcttcag tgcagatgtc cttcccaatgc tgcccaaaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcaactc tgacctagct agtgcctgtt 840
gcccagtgac ctgggggagc ctggctgcag gcccctcaatgc tgcccaaaaa 900
tgtgatttcag gtccccaggg gggactcagg gggaaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt cttagagggtc agaatattag ctccaggatc agctgggggt 1020
atggaaatgg ctgaggatca aacgtatgtat ggtgaaagga taccaggatg ttgctaaagg 1080
ttagggacag ttgggtttt ggacttacca ggtgtatgtt agatctggaa cccccaagtgc 1140
aggctgggg gagttaaaggc cttttttttt gatagggttggacagggtt ctttggaaatg 1200
aaagagtgac cttagagggc tccttgggcc tcaggaatgc tcctgtct gtgaagatga 1260
gaaggtgctc ttactcagtt aatgtatgact gactatattt accaaagccc ctacctgtc 1320
ctgggtccct ttagcacag gagactgggg ctaaggccc ctcccaaggga agggacacca 1380
tcaggccctc ggctgaggca gttagcataga ggatccattt ctacctgtat ttcccagagg 1440
actagcagga ggcagccctt agaaaaccggc agttcccaag ccagcgcctg gctgttctct 1500
cattgtcat gcccctccca caacccctcc tctaaccac tagagattgc ctgtgtccctg 1560
ccttgcctt ctgttagaat gcagctctgg ccctcaataa atgcttccctg cattcatctg 1620
aaaaaaaaaa

```

<210> 45

<211> 169

<212> DNA

<213> Human

<400> 45

tcttttgc tttagctttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaaacttgt ttatgatctt cagtcgtatt ccagtgtcataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagtga

<210> 46

<211> 769

<212> DNA

<213> Human

<400> 46

<210> 47

<211> 2529

<212> DNA

<213> Human

<400> 47

<210> 48

<211> 1553

<212> DNA

<213> Human

45 <400> 48

5400> 19

400

tttttttttt

ttcatata

aaatccatctt ataccacatc atgtatgtat acatcacatc agacacatcat accyaaagtt 150
ctaggccaggc ccgttttcca tcctctaaga cccattcttc atttggggccc ttctagggtt 240
ggggccctga gcttggttg tagaagttt gtgctaataat aaccatagct ttaatccccca 300
tgaaggacag tgtagacctc atctttgtct gctccccgct gccttcagtttacgttat 360
ccatcaagag ggctatggga gccaagtgaa cacggggat tgaggctaat tcacctgaa 420
tcgaaaaacag cgccccagtt cctccacgcg ggcacgcgtc tttttttttt ttccctcg 480
gacggagact cgctgttgtt cccaggctgg atgtcagttt caccgttcg gtcactgtca 540
agctccacct cctggattca taccattctc ctgttcgtc cttcccgagta gctggggacta 600
tagtgtgccaa ccactacgccc tagetaatttttttgtat ttttagtaga gacagggttt 660

caccgtgtta gccaggatgg tctcgccctg actttgtat ccggccccct cggcctccca 720
 aagtgcgtgg attacaggcg tgagccacca cacctggccc cggcacgtat cttaagga 780
 atgacacccag ttccctggctt ctgaccaaag aaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtggtggcag caacactgca gtcgttctg gatgtcgtg ggggtctc 900
 cggagcgggt gtgaacagcg cactcaaca tgagcaggcg cctggctccg gtgtgcctc 960
 acttcagtgg tgcaccccttga tggtggaaagc cagcccttgg ggcaggaaac cagtcagag 1020
 aggctaccca gtcagctgc tggcaggagc caggtattta cagccataat gtgttaaag 1080
 aaaaacacac ttctgcaga aacttccta cccgctcggg agactgggc tccttgcetg 1140
 ggatgacgtt cactcaacgt ggagatgggt gtggactgtt ccctgaaaag cggcccttgc 1200
 agggcaagt gaggtctca ggtcttaac ccagtggccc tctgaaagg ggtgtgcagg 1260
 cgaggggagc aggaggcttctc tctctagtcc ctttgaggc tttggcttag agaagagtga 1320
 gcaggagact gggaatggc caggcaggga aaggagactga agtattccgc ggctaatgcc 1380
 tcagatcgat gtatttcctc ccctggctc cccgagccct ctgtcaccc ctgctgcct 1440
 gcaggaggcc catctttctt gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 tacgagaccc ggggtagcgt gatctctgc ttccctgagc gcctgcacgg cag

15 <210> 49
 <211> 921
 <212> DNA
 <213> Human

20 <400> 49

ctgtggtccc agctactcag gaggctgagg cgggaggatt gtttggcccc aggagttgg 60
 ttttgcgtg agccaaatc gcaccattgc cttccactct gggccacgg acaataccct 120
 gtctcagaaa acaaacaaca aaaagcagaa acgctgaagg ggtcggttta cggaaaaacc 180
 gcctgtcaga acacttggct actcttaccc cagatcgtg gacctggaa tgagggttgg 240
 25 tcccccggagg ctttttccca agctgttgc accagacccg ccatggggac ccttggccaca 300
 gaagccccc ggggagtgag ccagagctg gaccgctgtg ctgtatgtc tgggggtggag 360
 ggagggtggg gagtgtcaaa ggggtgtgt gtccccgggg ggttcatg ggcagcatg 420
 tgcgtgcctg tttgtgtcg tgccttccca ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcaca ccttctgagc attgtctgtc cacgtgagac tgccagaga cagcagagct 540
 30 ccacgtgggtt taaaggggag acctttccctt gacccctgggg gtctcgccgt atctcatgac 600
 cagggtctaa atgaccgc atgcattacc tgcctttcga tgaccaacct ccctgtcccc 660
 gtcccgctga cctgcccccg tggcgctca cggtgatgcc tgcctctgac attgtgttcc 720
 actgttagcaa actacattct ggatggaaat ttcatgtac atgtgtgca tggaaaat 780
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgggtccctt ccagcacgg 840
 tactttgacc tcttgctac aacccttcc ttgggtccga ggctggtagc ttttttact 900
 tcagatgggtt gggggccgggt g

35 <210> 50
 <211> 338
 <212> DNA
 <213> Human

40 <400> 50

atgatctata tagatccctt accgtaaaat caaaaacacaa aaccctactg actcattccc 60
 tccctccag atattacccc atttctctac ttccattgtt agccaaactt tccaaaaatt 120
 catgttctgt ctccatttcc tcaatgttca cccaccctgt cttagctacc acccctcagt 180
 aacgacactag cctgggtaga aaaaatgtc agcatgatac cataactcaat gatcttcgt 240
 45 caactgttgc attgtcatca ttccatggcc ttactttccc tctcagcggcc atttgctaca 300
 gtaagaaaact ttcttttgtt aatttttgtt tcttttgtt

<210> 51
 <211> 1191
 <212> DNA
 <213> Human

50 <400> 51

ctagcaagca ggttaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgtt ctagagcaga ggctgattaa acactcgtg tgggtgcctt ctgtgcact 120
 55 cctggaaaat aatgaattgg gtaaggaaca gtaataaaga aaatgtgcct tgctaaactgt 180
 gcacattaca acaaagagct ggcagctctt gaaaggaaaag ggcttgcgc gctggcggttc 240
 aaaattgtca gtcaactcat gccacacgg tcagcgtctg cttccctcagc acaccctcat 300

EP 1 166 798 A1

<400> 56

<210> 57

30 <211> 460
<212> DNA
<213> Human

<400> 57

35	ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta ggcataatgt 60 gcctccaggg ggctgcagat gtgtctgagg gtgaggcctgg taaaagagaa gacaaaagaa 120 tggaaatgagc taaagcagcc gcctggggtg ggagggcag cccatttcta tgcatcgagg 180 ggcaggagcc cagcaaggaa gcctccattc ccaggaactt ggagggagct gagaccatcc 240 atggcccgag agccccctct cacactcact cctgttccagc cctaatttgtg caggtgggga 300 aactgaggct ggaaagtca atagcaatgt actggcagag ctgggactgg aacccaacca 360 40 gcctccataga ccacggttct tcccatcaat ggaatgttag agactccagc caggtgggta 420 ccgagctcgaa attcgtaatc atggtcatacg ctgtttctgt
----	---

<210> 58

<211> 1049
<212> DNA
<213> Human

<400> 58

	atctgtatcaa	gaatacacctgc	cctggtcaact	ctgcgcgatgt	ttctgtccac	ttgttcacat	60
	tgaggaccaa	gatataccttt	tttacagagg	cacttgttcg	gtctaaca	caca	120
	tgacgacatg	ctggctcaca	ttttgcagt	ctgcagaagt	ccccctccca	gcctggacta	180
	cagcagcact	ttcccgtggg	ggtgcagtag	ccgttgcac	agagcctgga	gcactctgaa	240
	gtcagtgtct	gtgcagggtt	taccgtggct	ctgcatttc	caggcattaa	aggctttt	300
	ggatctacaa	ttttgttagag	ttttccattt	tgagtc	tttttt	actgtttt	360
	aaaatgtaaa	cttcacccat	ttcatctt	ccaaatccca	agatgtgacc	ggaaaagt	420
	cctctacagg	accacctgt	ggcgacac	agtgg	tttgcact	cttgcac	480
	ggactttgt	ggagagttt	gaaattccca	ttacatctc	caaacacgt	gtttccat	540
	aatctttctg	actggcagcc	ccggatata	aatccaccaa	ccaaaggacc	attactgaat	600
	ggcttgaatt	ctaaaagtgt	tggctca	tctataat	ttccctttat	tatctgtaga	660

atctggctg atgatctgtt tttccattg gagtctgaac acagtatcgtaaattgatg 720
 ttatatacg tggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 5 aacacttcgg gggctgggt ggtgtgtt aagtgtgggt tgctccttgg tatggaataaa 840
 ggcacgttgc acatgtctgt gtccacatcc agccgttagca ctgagcctgt gaaatcactt 900
 aaccatcca ttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaacccgt cagggccaaa gagcagtgc cctccagat gcttctgtg gagttctgca 1020
 acttcaagaa agactctggc tggtctcaa

10 <210> 59
 <211> 747
 <212> DNA
 <213> Human

15 <400> 59

20 ttttcaaat cacatatggc ttcttgacc ccatcaaata actttattca cacaacgtc 60
 cctaattta caaaggctca gtcattcata cacattagg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaacccaag taaaccaagt aaaaaaaaaa ttcatataaa 180
 gttgttcaca cgtgggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgcct ggcttaaac ctccctcactg 300
 25 ctcgtctgtc ccacacaaat gtttaagaag tcactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420
 gcttccttag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ctttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctgggtgatg gctgttagatg ctaacactgg 540
 ccaattcaat gccacaccca ctgggttaccc tttagggca tttctccaga cagaagcccc 600
 ttgaaggccta ggttagggcag gatcagagat acacccgtgt ttgtctcgaa gggctccaca 660
 gcccagtacg acatgcttc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcaattta gtagtaatag cggccgc

30

Claims


1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.
7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as

compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
5
9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutic application.
10
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
 - a) compounds which inhibit receptor tyrosine kinase activity,
 - b) compounds which inhibit ligand binding to receptors,
 - c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
15
 - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
20
 - f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
 - g) compounds which inhibit receptor tyrosine kinase activity,
 - h) compounds which inhibit ligand binding to receptors,
 - i) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
25
 - k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
30
 - l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
- 35
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
40
14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.
15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small
45 molecule of general formula I

50

55



in which


20 r has the meaning of 0 to 2;

n has the meaning of 0 to 2;

R₃ und R₄ a) each independently from each other have the meaning of lower alkyl,
b) together form a bridge of general partial formula II,

25

30




35

wherein the binding is via the two terminal C-atoms,
and

40 m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

45



50

wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the binning is via the atoms T₁ and T₄;

G has the meaning of C₁-C₆-alkyl, C₂-C₆-alkylene or C₂-C₆-alkenylene; or C₂-C₆-alkylene or C₃-C₆-alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂, oxa (-O-), thia (-S-) or imino (-NH-),


A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
5 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
X has the meaning of imino, oxa or thia;
Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted
10 or substituted cycloalkyl; and
Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl,
hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N, N-disubstituted carbamoyl, amidino, guanidino, mercapto,
sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different
15 from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof,

15

and/or a compound of genaral formula IV

20



25

30


in which

35

- A has the meaning of group =NR²,
W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,
Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group


40


45

or A, Z and R¹ together form the group

50

55





	m, n and o	has the meaning of 0 - 3,
	q	has the meaning of 1 - 6,
15	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/or R _a and/or R _b together with R _c and/or R _d or R _c together with R _e and/or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
20	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
25	p	has the meaning of integer 1-4,
	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
30	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogen or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or C ₁₋₆ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R ⁵ and R ⁶ together form the group

35

	R ⁸ , R ⁹ and R ¹⁰	independently from each other have the meaning of hydrogen or C ₁₋₆ -alkyl, as well as their isomers and salts,
40		and/or a compound of general formula V




55

V,

in which


R¹ has the meaning of group

5



10

15




20

in which R⁵ is chloro, bromo or the group -OCH₃,

25

30




35

in which R⁷ is -CH₃ or chloro,

45

50



in which R⁸ is -CH₃, fluoro,
chloro or -CF₃


in which R⁴ is fluoro,
chloro, bromo, -CF₃,

-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R⁶ is
-CH₃ or chloro

R² has the meaning of pyridyl or the group

55



and

10 R³ has the meaning of hydrogen or fluoro, as well as their isomers and salts.

- 15 16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.
- 20 18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.
- 25 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
- 30 21. Use of pharmaceutical compositions according to claims 1-20, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiobroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

40

45

50

55




Fig. 1



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 00 25 0194 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 98 35958 A (NOVARTIS ERFINDUNGEN VERWALTUNG ;CIBA GEIGY AG (CH); TRAXLER PETER) 20 August 1998 (1998-08-20) * abstract * * page 1, paragraph 1 *	1-15, 21	A61K45/06
A	KOBLIZEK, THOMAS I. ET AL: "Angiopoietin-1 induces sprouting angiogenesis in vitro" CURR. BIOL. (1998), 8(9), 529-532 , XP000972727 * page 531, column 1, paragraph 2 *	1-21	
A	SCHLAEPPPI, JEAN-MARC ET AL: "Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors." CANCER AND METASTASIS REVIEWS, (1999) VOL. 18, NO. 4, PP. 473-481. PRINT. , XP000972749 * page 477, column 2, paragraph 2 - page 478, column 1, paragraph 1 *	1-21	
			TECHNICAL FIELDS SEARCHED (Int.Cl.)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims</p> <p>Claims searched completely</p> <p>Claims searched incompletely</p> <p>Claims not searched</p> <p>Reason for the limitation of the search see sheet C</p>			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	12 January 2001	Leherte, C	
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			



European Patent
Office

**INCOMPLETE SEARCH
SHEET C**

Application Number
EP 00 25 0194

Claim(s) searched completely:

17-20

Claim(s) searched incompletely:

1-16, 21

Reason for the limitation of the search:

Present claims 1-16,21 relate to compounds defined by reference to desirable characteristics or properties, namely :
 " agents which modulates the biological function of one or several of the VEGF/VEGF receptor systems",
 " agents which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems",
 " agents which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems",
 " agents which are targeted to the endothelium",
 " agents which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems",
 " agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of the Angiopoietin/Tie receptor systems",
 " compounds which inhibit receptor tyrosine kinase activity",
 " compounds which inhibit ligand binding to receptors",
 " compounds which inhibit activation of intracellular signal pathways of the receptors",
 " compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor systems",
 " delivery systems, which target cytotoxic agents or coagulation-inducing agents to the endothelium",
 "delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis",
 " compounds of general formula I, IV or V".

The claims cover all compounds having those characteristics, properties or formulas, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the pharmaceutical compositions mentioned in the claims 17-20, with due regard to the therapeutic applications mentioned in claim 21.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 25 0194

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-01-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9835958 A	20-08-1998	AU 6621898 A	08-09-1998
		BR 9807685 A	21-03-2000
		CN 1251097 T	19-04-2000
		CZ 9902853 A	17-11-1999
		EP 0970070 A	12-01-2000
		NO 993888 A	11-10-1999
		PL 335113 A	10-04-2000
		SK 109699 A	13-03-2000
		ZA 9801155 A	13-08-1998